Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Reich

Showing results (171-180 of 218) with videos related to

Pageof 22
Sort By:
The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.
The British Journal of Dermatology|October 14, 2014
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-upR G Langley, M Lebwohl, G G Krueger, et al.
The British Journal of Dermatology|October 15, 2013
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)C Paul, L Puig, K Kragballe, et al.
Nucleic Acids Research|June 11, 1994
Direct detection of nucleic acid hybridization on the surface of a charge coupled deviceJ B Lamture, K L Beattie, B E Burke, et al.
The British Journal of Dermatology|May 13, 2017
Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasisA Blauvelt, K Reich, R B Warren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 3, 2017
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trialsL Guenther, R B Warren, J C Cather, et al.
The British Journal of Dermatology|June 9, 2021
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2K Reich, K B Gordon, B E Strober, et al.
The British Journal of Dermatology|October 15, 2013
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasisK Reich, L Puig, C Paul, et al.
The British Journal of Dermatology|June 5, 2015
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trialK Papp, D Thaçi, K Reich, et al.
The British Journal of Dermatology|January 11, 2013
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upK A Papp, C E M Griffiths, K Gordon, et al.
Pageof 22

Showing results (171-180 of 218) with videos related to

Sort By:
Pageof 22
The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.
The British Journal of Dermatology|October 14, 2014
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-upR G Langley, M Lebwohl, G G Krueger, et al.
The British Journal of Dermatology|October 15, 2013
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)C Paul, L Puig, K Kragballe, et al.
Nucleic Acids Research|June 11, 1994
Direct detection of nucleic acid hybridization on the surface of a charge coupled deviceJ B Lamture, K L Beattie, B E Burke, et al.
The British Journal of Dermatology|May 13, 2017
Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasisA Blauvelt, K Reich, R B Warren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 3, 2017
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trialsL Guenther, R B Warren, J C Cather, et al.
The British Journal of Dermatology|June 9, 2021
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2K Reich, K B Gordon, B E Strober, et al.
The British Journal of Dermatology|October 15, 2013
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasisK Reich, L Puig, C Paul, et al.
The British Journal of Dermatology|June 5, 2015
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trialK Papp, D Thaçi, K Reich, et al.
The British Journal of Dermatology|January 11, 2013
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upK A Papp, C E M Griffiths, K Gordon, et al.
Pageof 22